Atellas
Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia
July 16, 2020Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib
NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
